Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
NCT ID: NCT01098162
Last Updated: 2014-09-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
576 participants
OBSERVATIONAL
2010-03-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy
NCT01673282
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
NCT01236001
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
NCT00771927
Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
NCT02276053
Voronistat in Pediatric Patients With Drug Resistant Epilepsy
NCT03894826
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vimpat®
Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The decision to prescribe Vimpat® has to be made by the physician before and independently of his/her decision to include the patient in the study
* The Vimpat® treatment should have been started not longer than 2 weeks before study inclusion of the patient
* The patient must have a diagnosis of Epilepsy with Partial-Onset Seizures
* Based on the physician's clinical judgment, the patient's seizure activity is not controlled sufficiently on a current monotherapy and it is in the patient's best interest to be prescribed adjunctive Vimpat®
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
55
Aachen, , Germany
119
Aalen, , Germany
194
Aichach, , Germany
191
Altenburg, , Germany
136
Alzenau in Unterfranken, , Germany
78
Aschaffenburg, , Germany
35
Bad Berka, , Germany
90
Baesweiler, , Germany
107
Berlin, , Germany
10A
Berlin, , Germany
141
Berlin, , Germany
25
Berlin, , Germany
49
Berlin, , Germany
66
Berlin, , Germany
75
Berlin, , Germany
36
Bielefeld, , Germany
5
Bonn, , Germany
192
Böblingen, , Germany
175
Brandenburg, , Germany
105
Chemnitz, , Germany
176
Cologne, , Germany
180
Cologne, , Germany
182
Coppenbrügge, , Germany
161
Dortmund, , Germany
128
Dresden, , Germany
21
Dresden, , Germany
39
Dresden, , Germany
111
Düren, , Germany
38
Düsseldorf, , Germany
7
Eberswalde, , Germany
102
Eisenach, , Germany
174
Eisenach, , Germany
56
Ellwangen, , Germany
50
Erbach im Odenwald, , Germany
179
Erfurt, , Germany
186
Erfurt, , Germany
6
Erlangen, , Germany
12
Essen, , Germany
27
Freiburg im Breisgau, , Germany
137
Fulda, , Germany
112
Gelsenkirchen, , Germany
103
Gera, , Germany
158
Göttingen, , Germany
65
Göttingen, , Germany
88
Göttingen, , Germany
1
Greifswald, , Germany
47
Grevenbroich, , Germany
134
Halle, , Germany
160
Hamburg, , Germany
71
Hamburg, , Germany
93
Hamm, , Germany
147
Heilbronn, , Germany
122
Herborn, , Germany
15
Herdecke, , Germany
130
Höchberg, , Germany
40
Immenstadt im Allgäu, , Germany
52
Jena, , Germany
61
Jülich, , Germany
44
Karlstadt am Main, , Germany
133
Kastellaun, , Germany
125
Kaufbeuren, , Germany
16
Kiel, , Germany
99
Kleve, , Germany
37
Krefeld, , Germany
46
Lappersdorf, , Germany
113
Leipzig, , Germany
4
Leipzig, , Germany
68
Leipzig, , Germany
81
Leipzig, , Germany
138
Lohr a. Main, , Germany
131
Ludwigsburg, , Germany
148
Lüdenscheid, , Germany
33
Mainz, , Germany
154
Mannheim, , Germany
151
Mühlhausen, , Germany
101
München, , Germany
167
München, , Germany
2
München, , Germany
43
Neuburg am Inn, , Germany
62
Neukirchen-Vluyn, , Germany
123
Neumarkt, , Germany
69
Nuremberg, , Germany
80
Oelde, , Germany
98
Oldenburg, , Germany
87
Oranienburg, , Germany
57
Potsdam, , Germany
3
Radeberg, , Germany
159
Rathenow, , Germany
45
Ravensburg, , Germany
95
Rostock, , Germany
85
Rüsselsheim am Main, , Germany
20
Schleswig, , Germany
157
Schlüchtern, , Germany
166
Schorndorf, , Germany
181
Schriesheim, , Germany
150
Schwäb. Gmünd, , Germany
168
Schwedt, , Germany
140
Senftenberg, , Germany
164
Siegen, , Germany
144
Sondershausen, , Germany
127
Stralsund, , Germany
14
Stuttgart, , Germany
170
Stuttgart, , Germany
104
Traunstein, , Germany
183
Troisdorf, , Germany
17
Tübingen, , Germany
13
Ulm, , Germany
48
Ulm, , Germany
54
Unterhaching, , Germany
171
Wermsdorf, , Germany
143
Westerstede, , Germany
79
Wismar, , Germany
169
Wolfratshausen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Runge U, Arnold S, Brandt C, Reinhardt F, Kuhn F, Isensee K, Ramirez F, Dedeken P, Lauterbach T, Noack-Rink M, Mayer T. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study. Epilepsia. 2015 Dec;56(12):1921-30. doi: 10.1111/epi.13224. Epub 2015 Nov 3.
Related Links
Access external resources that provide additional context or updates about the study.
Product Information
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP0973
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.